A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression Upon Drug Administration

Cancer immunology research - United States
doi 10.1158/2326-6066.cir-16-0043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

169. Clinically Adaptable CD19-Specific Chimeric Antigen Receptor

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

Characterization of Clinical Grade CD19 Chimeric Antigen Receptor T Cells Produced Using Automated CliniMACS Prodigy System

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Cytokine Release Syndrome and Neurotoxicity After CD19 Chimeric Antigen Receptor-Modified (CAR-) T Cell Therapy

British Journal of Haematology
Hematology
2018English

Haemophagocytic Lymphohistiocytosis Has Variable Time to Onset Following CD19 Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2019English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

74. The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-Cd19 Chimeric Antigen Receptor

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Chimeric Antigen Receptor T Cell Therapies for Multiple Myeloma

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy